Anthos Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Anthos Therapeutics Inc.
Bristol and Janssen reported Phase II data at the ESC Congress in secondary stroke prevention, an indication not covered by Factor Xa inhibitors. BMS unveiled a three-indication Phase III program.
CEO John Glasspool spoke with Scrip about why Anthos believes it has a good shot against big competitors in a market that is expected to generate blockbuster sales across multiple products.
The potential for RNA medicines to achieve holy grail goals – reaching undruggable targets and bringing drugs to market faster – has Pfizer, Lilly, Novartis and others in a deal-making frame of mind.
With cash to spend and a patent cliff to overcome starting in 2025, Pfizer is expected to be a prolific deal-maker in 2022.
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.